Molina's Twin Pivot: Exchange Acuity Shock and the Duals Lift
Q2 2026 raises EPS guidance but exposes a deeper marketplace loss; 2027 reshapes premium mix toward Medicare duals and away from a troubled exchange book.
MOH · Earnings Call · 2026-07-23
The Guidance Recipe
Molina beat on EPS guidance – raising to at least $5.25 from at least $5 – but the composition is telling. The increase is entirely Medicaid (up $0.25) and Medicare duals (up $1.50), while the marketplace swung to a loss of $0.75 per share. As CFO Mark Keim put it: “Excluding those items, our 2026 earnings power is at least $7.75 per share.” — Mark Keim, CFO · 2026-07-23 That $2.50 of non-recurring drag – the Florida CMS implementation and the MAPD exit – is exactly what the 2027 building blocks are designed to recover.The Marketplace Muddle
The big negative is the exchange book. MCR guidance for Marketplace jumped from 85.5% to 90%, driven by prior-year risk adjustment true-ups and an adverse member acuity mix. Joe Zubretsky admitted bluntly:This is not a new problem – Molina has been cutting exchange footprint for years – but the scale of the miss is new. The company is now guiding to a $0.75 loss for 2026, a $1.50 swing versus the prior gain guidance. Management's response: cut another ~$1 billion of premium in 2027, concentrating membership in about six states. As Joe explained, high-cost members on therapies like HIV or oncology stick with the plan even when prices rise, but they don't generate commensurate HCC codes. CFO Mark Keim added: “not all medical expense is risk adjustable.” — Mark Keim, CFO · 2026-07-23 This is a structural issue the company can't fully hedge by repositioning.It literally is in a declining book of business, that acuity shift was underestimated in pricing, pure and simple.
The Duals Silver Lining
The offset is Medicare duals, which outperformed dramatically. The company had priced conservatively, assuming 6% trend; it's now expecting 4%. That single change lifted the Medicare segment by $1.50 per share. As Joe said: “We were consciously and purposely conservative in forecasting guiding on medical cost trend, which we picked at 6%. It's our new forecast is it's going to come in at 4%.” — Joseph Zubretsky, President and CEO · 2026-07-23 The duals product (FIDE/HIDE and D-SNP) is now the flagship, and management argues the 1.4% pretax margin in its first year is above the 2.5% target trajectory.2027 Building Blocks
Molina laid out a 2027 premium outlook of $46.5B, down from the $48B Investor Day target, due to marketplace de-emphasis and California's decision to move undocumented members to fee-for-service (a ~$500M hit). But EPS building blocks sum to more than $10/share, assuming marketplace reaches breakeven, the Florida CMS contract reverses its $1.50 drag, and Medicaid rate/trend imbalance corrects. The core assumption is that Medicaid is underfunded by 300 bps, and every 100 bps of MCR improvement is worth $5/share. State actuaries are expected to capture this in 2027 rates, especially with 55% of premium renewing on January 1. The company is also leaning on G&A leverage. Joe: “G&A leverage alone should pull the G&A ratio down below 6%.” — Joseph Zubretsky, President and CEO · 2026-07-23 That's a recurring theme, but the realistic deployment of AI to cut administrative costs is framed as upside, not embedded. The numbers corroborate the struggle. Operating income swung from $428M in Q1 2025 to a loss of $162M in Q4 2025, and back to just $83M in Q1 2026. The balance sheet remains strong, with effective net cash of $5.6B and a debt-to-cap ratio of ~47%. Free cash flow was $1.0B in the latest quarter, but that's partly timing. MOH stock is up 37% over the last 90 days, despite being 52% below its 2024 peak. The market is rewarding the duals surprise and the clean 2027 setup, while discounting the marketplace noise. The real story is the Marketplace guidance cut – it's a deliberate, ongoing de-risking that trades revenue for stability. The company is essentially betting its future on dual eligibility and managed Medicaid, which is a coherent strategy if states fund rates adequately. From a prior call, the philosophy is unchanged:That says it all. This is a mixed quarter – a positive surprise on EPS and duals, but a negative surprise on marketplace that forces a strategic pivot. The 2027 outlook looks credible only if Medicaid rates catch up, which is the big swing factor.we don't like to allocate capital to a product in an unstable risk pool.